<DOC>
	<DOCNO>NCT01024894</DOCNO>
	<brief_summary>This study design evaluate safety biological active dose new experimental drug , IL-7 , combination standard bi-therapy Asiatic patient Hepatitis C chronic infection identify non responder standard bi-therapy alone .</brief_summary>
	<brief_title>Dose Escalation Study Interleukin-7 ( IL-7 ) Bitherapy Asiatic HCV Patients Resistant Bitherapy</brief_title>
	<detailed_description>This Phase I/IIa inter-patient dose-escalation study assess weekly dos Interleukin-7 ( CYT107 ) Asiatic adult patient infect virus genotype 1 Hepatitis C resistant standard treatment Peg-Interferon Ribavirin ( bi-therapy ) . The dose escalation aim establish safety biologically active dos CYT107 add combination therapy pegylated interferon-alpha ribavirin . At dose level , study patient receive one subcutaneous administration CYT107 per week total 4 . Groups 3 6 patient enter dose level CYT107 . Three dose level plan . Eligible patient initially receive bi-therapy 6-10 week . Thereafter , CYT107 add cycle four weekly injection define dose level standard bi-therapy continue 9 week CYT107 treatment discontinuation . The patient follow regular basis reach 48 week CYT107 treatment . The duration study approximatively 60 week 20-25 week bi-therapy . Participants 1 overnight hospitalization 15 clinic visit period 60 week . During visit follow may do : - medical history , physical examination , blood test - electrocardiogram ( ECG ) - chest X-Ray - liver/spleen image - urine test</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Main HCV Genotype 1 infect patient Absence viral response previous treatment pegylated interferonalpha plus ribavirin Metavir â‰¤ F3 assess biopsy last 12 month Main Active infection HBV Infection HIV1 /or HIV2 Apart HCV infection , presence active infection require specific treatment hospitalization Other liver disease Body mass index ( BMI ) &gt; 30kg/m2 Relapse previous response pegylated IFN alpha ribavirin therapy Previous bitherapy pegylated IFN alpha ribavirin well tolerate ( particular treatment discontinuation ) Any history malignancy apart curatively treat basal cell carcinoma situ cervical carcinoma History clinical autoimmune disease active autoimmune disease History severe asthma , presently chronic medication Significant cardiac pulmonary disease Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune-based therapy</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>chronic hepatitis</keyword>
	<keyword>resistance Peg-interferon ribavirin bitherapy</keyword>
	<keyword>immune specific response HCV</keyword>
	<keyword>taiwan</keyword>
	<keyword>phase 1/2a</keyword>
	<keyword>viral disease</keyword>
	<keyword>liver disease</keyword>
</DOC>